PENTACAM STUDY OF VAULT CHANGES AFTER TROPICAMIDE 1% AND CYCLOPENTOLATE 1% INSTILLATION IN MYOPIC EYES WITH IMPLANTABLE PHAKIC CONTACT LENS

Purpose: to compare the vault changes, anterior segment parameters, and intraocular pressure (IOP) after pharmacological mydriasis by tropicamide 1% and cyclopentolate 1% in moderate-to-high myopic eyes with Implantable Phakic Contact Lens (IPCL). Methods : a prospective observational study 48 myopic eyes were implanted with IPCL V2.0 (Care group Sight Solutions , India). Pharmacological mydriasis was done by tropicamide 1% and cyclopentolate 1%. The patients were divided into 2 groups, group 1 was dilated by tropicamide1 % and group 2 was dilated by cyclopentolate 1%. The Pentacam was used to evaluate the lens vault, anterior chamber depth (ACD ), anterior chamber volume (ACV), pupil size, and endothelium-IPCL (end-IPCL). Also, IOP was evaluated and compared between both groups. Results : the Pentacam study of both groups revealed significant changes regarding the vault, ACD, ACV, and pupil size with no significant difference in end-IPCL (p-value= 0.884 and 0.880) in groups 1 and 2 respectively. And no significant difference when comparing both groups with each other. Regarding IOP, there was a significant difference in both groups with no significant difference when comparing both groups with each other (p-value=.295). Conclusion : pharmacological mydriasis in myopic eyes implanted with IPCL results in changes in the vault, ACD, and ACV with no significant difference between tropicamide 1% and cyclopentolate 1%. Both medications caused IOP elevation to a similar value so there was a need to recheck IOP post dilatation preferably at 45 minutes. So mydriasis with either tropicamide 1 % or cyclopentolate 1 % was relatively safe in eyes with IPCL implantation.